Nasdaq:TLPH
TALPHERA, INC.
A pre-revenue biotechnology or tech firm burning cash on R&D while maintaining a positive cash position funded by equity issuance.
Key Metrics
Investment Thesis
Bull Case
The company retains $8.9M in cash equivalents providing a runway to execute its R&D strategy without immediate dilution, while the recent financing activity suggests strong investor confidence in the long-term potential of its underlying technology or platform.
Bear Case
With zero revenue and a massive negative net profit trend from 2022 to 2024, the stock lacks fundamental valuation metrics like earnings or cash flow from operations, making it highly speculative dependent entirely on future product launches that have not yet materialized.
About TALPHERA, INC.
TALPHERA, INC. (TLPH) is a technology development entity with zero revenue and significant accumulated deficits, currently relying on substantial financing inflows to fund research and development initiatives.
Analysis
Management Discussion
Management has successfully secured $12.0M in financing cash flow to offset a net loss of $13.0M, yet the company faces a critical path where operating expenses of $15.3M far exceed any generated income, resulting in a retained earnings deficit of $-457.2M.
Industry Overview
The company operates in a high-risk early-stage sector where firms often trade on pipeline potential rather than current financials, characterized by significant R&D expenditures and the absence of traditional profit margins until commercialization occurs.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $1.8M | $651.0K | $0 |
| Cost of Revenue | $2.6M | $0 | $0 |
| Gross Profit | $-820.0K | $651.0K | $0 |
| Operating Expenses | $35.8M | $17.5M | $15.3M |
| Operating Income | $-36.6M | $-16.9M | $-15.3M |
| R&D | $5.2M | $5.5M | $6.7M |
| G&A | $25.7M | $12.0M | $8.5M |
| Stock-Based Comp | $2.9M | $1.7M | $989.0K |
| D&A | $1.6M | $311.0K | $0 |
| Depreciation | $800.0K | — | — |
| Other OpEx | $4.9M | $0 | $0 |
| Non-Operating Income | $84.4M | $6.6M | $2.2M |
| Interest Expense | $1.2M | $134.0K | — |
| Pre-Tax Income | $47.8M | $-10.3M | $-13.0M |
| Income Tax | $13.0K | $0 | $0 |
| Continuing Ops | $47.8M | $-10.3M | $-13.0M |
| Discontinued Ops | $0 | $-8.1M | $0 |
| Net Income | $47.8M | $-18.4M | $-13.0M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $47.8M | $-18.4M | $-13.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $24.6M | $11.6M | $9.4M |
| Cash & Equivalents | $15.3M | $5.7M | $8.9M |
| Marketable Securities | $495.0K | $3.7M | $0 |
| Accounts Receivable | $309.0K | — | — |
| Inventory | $1.2M | — | — |
| Prepaid Expenses | $2.3M | $2.2M | $554.0K |
| Other Current Assets | $5.0M | $0 | $0 |
| Long-Term Assets | $22.9M | $8.8M | $8.8M |
| PP&E (Net) | $10.3M | — | — |
| Intangibles | $8.8M | $8.8M | $8.8M |
| Operating Leases | $3.6M | — | — |
| Other LT Assets | $246.0K | $20.0K | $0 |
| Total Assets | $47.5M | $20.4M | $18.2M |
| Current Liabilities | $13.8M | $4.5M | $2.6M |
| Accounts Payable | $2.0M | $1.3M | $670.0K |
| Current Debt | $5.8M | $0 | — |
| Current Leases | $1.7M | — | — |
| Other Current Liab | $0 | $731.0K | $723.0K |
| Long-Term Liabilities | $11.9M | $1.8M | $7.6M |
| Long-Term Debt | $0 | — | — |
| LT Operating Leases | $3.0M | — | — |
| Other LT Liab | $7.9M | — | — |
| Total Liabilities | $25.7M | $6.3M | $10.2M |
| Shareholders' Equity | $21.8M | $14.1M | $8.0M |
| Paid-In Capital | $447.6M | $458.3M | $465.2M |
| Retained Earnings | $-425.8M | $-444.2M | $-457.2M |
| Total L&E | $47.5M | $20.4M | $18.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $47.8M | $-18.4M | $-13.0M |
| Non-Cash Adjustments | $-74.6M | $3.1M | $3.8M |
| Working Capital Changes | $-1.5M | $-2.2M | $-3.5M |
| Cash from Operations | $-28.3M | $-17.5M | $-12.7M |
| Capital Expenditures | $364.0K | $100.0K | $0 |
| Cash from Investing | $36.5M | $-528.0K | $3.8M |
| Debt Repayments | $8.4M | $5.4M | $0 |
| Cash from Financing | $-507.0K | $3.5M | $12.0M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $7.6M | $-14.6M | $3.1M |
| Beginning Cash | $12.7M | $20.3M | $5.7M |
| Ending Cash | $20.3M | $5.7M | $8.9M |
Frequently Asked Questions
How does TALPHERA, INC. make money?
The company operates as a single pre-commercial entity with no current revenue streams, directing all operational expenditures toward general and administrative costs and substantial research and development efforts totaling $6.7M in the latest period.
What are the main risks for TLPH?
Complete lack of revenue generation with zero cost of goods sold and gross profit indicates no current product-market fit; severe profitability concerns with net losses widening from $47.8M to $-13.0M over the recent period; heavy reliance on external financing as cash flow from operations turned negative at $-12.7M.
What is TLPH's competitive advantage?
Access to large capital markets evidenced by $12.0M in financing cash flow, a clean balance sheet with zero debt repayments, and significant non-cash adjustments suggesting potential future asset revaluations or accounting flexibility.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.